Definitions
According to the World Health Organization (WHO), multisource pharmaceutical products or generic products are “pharmaceutically equivalent or pharmaceutically alternative products that may or may not be therapeutically equivalent” [1]. According to that same organization, when multisource pharmaceutical products are therapeutically equivalent, they can be considered interchangeable.
Pharmaceutical alternatives are products that contain the same active pharmaceutical moiety or moieties but differ in dosage form (e.g., tablets versus capsules), strength, and/or the chemical form of the active ingredient(s) (for instance, different salts or different esters) [1, 2]. Pharmaceutical alternatives must deliver the same active moiety by the same route of administration [1]. On the other hand, pharmaceutical equivalentscontain the same molar amount of the same active pharmaceutical...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
WHO Expert Committee on Specifications for Pharmaceutical Preparations N° 992. Annex 7 multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. 2015. Available from: https://www.who.int/medicines/areas/quality_safety/quality_assurance/expert_committee/WHO_TRS_992_web.pdf
European Agency (EMA) Committee for Human Medicinal Products (CHMP). Guideline on the investigation of bioequivalence Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. 2010. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf
European Agency (EMA) Committee for Human Medicinal Products (CHMP). European Medicines Agency procedural advice for users of the centralised procedure for generic/hybrid applications Doc. Ref. EMEA/CHMP/225411/2006. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/european-medicines-agency-procedural-advice-users-centralised-procedure-generic/hybrid-applications_en.pdf.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) Guidance for Industry Referencing Approved Drug Products in ANDA Submissions. October 2020. Available from: https://www.fda.gov/media/102360/download
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs -General Considerations Draft Guidance. March 2014 Biopharmaceutics. Available from: https://www.fda.gov/files/drugs/published/Bioavailability-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2%80%94-General-Considerations.pdf
European Commission Health and Food Safety Directorate -General. Revision 11 notice to applicants. volume 2A- Procedures for marketing authorization- Chapter a marketing authorization. July 2019. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/vol2a_chap1_en.pdf
Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, et al. The impact of generic substitution on health and economic outcomes: a systematic review. Appl Health Econ Health Policy. 2015;13(1):S21–33. https://doi.org/10.1007/s40258-014-0147-0.
Ferrario A, et al. Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ. 2020;368:15444. https://doi.org/10.1136/bmj.15444.
Conrad R, Lutter R. Generic competition and drug prices: new evidence linking greater generic competition and lower drug prices report. US. Food and Drug Administration. December 2019. Available from: https://www.fda.gov/media/133509/download
US Food and Drug Administration. Generic drug facts. 2018. Available from: https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
Lionberger R, Jiang W, Huang S-M, Geba G. Confidence in generic drug substitution. Clin Pharmacol Ther. 2013;94(4):438–40. https://doi.org/10.1038/clpt.2013.104.
Yu Y, Teerenstra S, Neef C, Burger D, Maliepard M. Investigation into the interchangeability of generic formulations using immunosuppressants and a broad selection of medicines. Eur J Clin Pharmacol. 2015;71:971–90. https://doi.org/10.1007/s00228-015-1878-z.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Quiroga, P.A.M. (2022). Bioequivalence Studies: Generic Products. In: Talevi, A. (eds) The ADME Encyclopedia. Springer, Cham. https://doi.org/10.1007/978-3-030-84860-6_131
Download citation
DOI: https://doi.org/10.1007/978-3-030-84860-6_131
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84859-0
Online ISBN: 978-3-030-84860-6
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences